暗盤前瞻 | 賽生藥業:認購火爆的生物醫藥企業,暗盤能否延續火熱?
uSMART盈立智投3月2日消息,今日賽生藥業公佈中籤結果,公佈招股結果,一手中籤率3%,認購140手穩中一手。乙頭穩2爭3,頂頭槌穩中20手。公開認購倍數爲1,068.05倍,國配認購倍數10倍,相比較公開認購的火爆,國配超購才10倍,相對遇冷證明在機構層面不是太受歡迎。並將於3月2日16:15-18:30進行暗盤交易。
賽生藥業主要在中國從事藥品研發,集中於腫瘤及重症感染領域,其營業額有約八成集中於其研發的產品「日達仙」,用於治療膿毒症、胰腺癌、肝癌及新型冠狀病毒。已上市的產品包括自有產品日達仙以及授權引入產品擇泰,另外一款授權引入產品安其思即將上市。
本次招股,賽生藥業引入11名基石投資者,包括Shanghai Pharmaceutical Lin-gang Special Area、Daguan International、China Post and Capital Global Asset Management等,合共認購10.4億元等值股份,約佔發行規模47.5%左右,設6個月禁售期。
從認購情況來看,乙組認購倍數高達1570倍,是甲組(566倍)的近3倍。乙組繼續呈"內卷"趨勢。乙組打和點在15%左右。
從行業表現來看,今年上市了7只生物醫藥股,除了昭衍新藥首日收跌8.61%以外,其餘都未破發,不過昭衍新藥主要是AH兩地上市新股,又趕上大盤行情回調,本週市場行情有所反彈但仍處在震盪調整時,且在招股期間,醫藥股都出現了大幅回調,賽生表現可能不會太樂觀。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.